0001005286-24-000112 | 10-Q | XBRL Viewer | Lifecore Biomedical INC DE

Organization, Basis of Presentation, and Summary of Significant Accounting Policies - Components of Inventories (Details) - USD ($) $ in Thousands	Feb. 25, 2024	May 28, 2023
Accounting Policies [Abstract]
Finished goods	$ 13,113	$ 13,141
Raw materials	18,686	17,735
Work in process	8,802	10,349
Inventory reserve	(931)	(384)
Inventories, net	$ 39,670	$ 40,841

Earnings Per Share

9 Months Ended

Feb. 25, 2024

Earnings Per Share [Abstract]

Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share:


	Three Months Ended				Nine Months Ended
(In thousands, except per share amounts)	February 25, 2024		February 26, 2023		February 25, 2024		February 26, 2023
Numerator:
Net income (loss) from continuing operations	$	14,785	$	(11,330)	$	16,417	$	(27,238)

Income (loss) from discontinued operations, net of tax	847		(25,177)		2,679		(33,041)
Net income (loss)	$	15,632	$	(36,507)	$	19,096	$	(60,279)

Denominator:
Weighted average shares for basic income (loss) per share	30,488		30,304		30,450		29,838
Potential preferred stock conversion to common stock	5,899		—		5,792		—
Dilutive stock options and RSUs	222		—		227		—
Weighted average shares for diluted income (loss) per share	36,609		30,304		36,469		29,838

Basic net income (loss) per share:
Income (loss) from continuing operations	$	0.48	$	(0.37)	$	0.54	$	(0.91)
Income (loss) from discontinued operations	$	0.03	$	(0.83)	$	0.09	$	(1.11)
Total basic net income (loss) per share	$	0.51	$	(1.20)	$	0.63	$	(2.02)

Diluted net income (loss) per share:
Income (loss) from continuing operations	$	0.40	$	(0.37)	$	0.45	$	(0.91)
Income (loss) from discontinued operations	$	0.02	$	(0.83)	$	0.07	$	(1.11)
Total diluted net income (loss) per share	$	0.42	$	(1.20)	$	0.52	$	(2.02)

Due to the Company’s net loss for the three months ended February 26, 2023, the net loss per share includes only the weighted average shares outstanding and thus excludes the potential dilutive effect of 87,670 RSUs; no stock options since they were all out of the money; and 38,750 Convertible Preferred Stock, as such impact would be antidilutive. All antidilutive items relate to the Company’s continuing operations.

Due to the Company’s net loss for the nine months ended February 26, 2023, the net loss per share includes only the weighted average shares outstanding and thus excludes the potential dilutive effect of 127,905 RSUs; no stock options since they were all out of the money; and 38,750 Convertible Preferred Stock, respectively, as such impact would be antidilutive. All antidilutive items relate to the Company’s continuing operations.

See Note 2 – Convertible Preferred Stock for more information on outstanding Convertible Preferred Stock and Note 3 – Stock-based Compensation and Stockholders’ Equity more information on outstanding RSUs and stock options.

Cover Page - shares	9 Months Ended
Cover Page - shares	Feb. 25, 2024	Aug. 05, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Feb. 25, 2024
Document Transition Report	false
Entity File Number	000-27446
Entity Registrant Name	LIFECORE BIOMEDICAL, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3025618
Entity Address, Address Line One	3515 Lyman Boulevard
Entity Address, City or Town	Chaska,
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55318
City Area Code	952
Local Phone Number	368-4300
Title of 12(b) Security	Common stock, par value $0.001 per share
Trading Symbol	LFCR
Security Exchange Name	NASDAQ
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		30,869,738
Entity Central Index Key	0001005286
Current Fiscal Year End Date	--05-26
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false

Restructuring Costs - Schedule of Costs (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		57 Months Ended
	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 771	$ 2,566	$ 918	$ 4,176	$ 30,874
Asset write-off costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs					13,893
Employee severance and benefit costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	76	2,187	215	2,282	4,314
Lease costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	684	43	700	88	4,814
Other restructuring costs
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 11	$ 336	$ 3	$ 1,806	$ 7,853

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

Debt - Narrative (Details)			9 Months Ended
Debt - Narrative (Details)	May 02, 2024 USD ($)	May 22, 2023 USD ($)	Feb. 25, 2024 USD ($)	Feb. 26, 2023 USD ($)	May 10, 2024 USD ($)	Dec. 31, 2023 person	May 28, 2023 USD ($)
Debt Instrument [Line Items]
Embedded derivative, fair value		$ 64,900,000	$ 23,000,000				$ 64,900,000
Total principal amount of long-term debt			160,820,000				150,233,000
Payments on long-term debt			386,000	$ 3,199,000
Credit guarantee agreement, support personnel threshold (more than) \| person						20
Equipment Sale and Leaseback Agreements
Debt Instrument [Line Items]
Sale leaseback transaction, net book value		$ 10,000,000
Option to repurchase, term		7 years
Proceeds from sales of property and equipment			7,700,000
Sale and leaseback transaction, gain (loss)			2,300,000
Price at end of term		$ 1.00
Quarterly rental payment to be received		0.025
Rental payment, purchase price less cumulative paydown payments made		1.50%
Other assets
Debt Instrument [Line Items]
Debt issuance costs			1,700,000				1,400,000
Other Current Assets
Debt Instrument [Line Items]
Debt issuance costs			900,000
Line of Credit \| Revolving Credit Facility
Debt Instrument [Line Items]
Total principal amount of long-term debt			$ 19,900,000				$ 16,800,000
Revolver interest rate			8.15%				12.16%
Line of credit, available borrowing capacity			$ 5,700,000
Term Loan Credit Agreement
Debt Instrument [Line Items]
Debt instrument, face amount		$ 142,300,000
Unamortized debt discount			63,700,000				$ 65,400,000
Term Loan Credit Agreement \| Subsequent Event
Debt Instrument [Line Items]
Payments on long-term debt	$ 5,500,000
Term Loan \| Line of Credit
Debt Instrument [Line Items]
Total principal amount of long-term debt			$ 153,477,000				$ 142,503,000
Revolver interest rate			10.00%				10.00%
Revolving Credit Agreement \| Revolving Credit Facility
Debt Instrument [Line Items]
Revolving line of credit		40,000,000
Line of credit reduction		$ 4,000,000
Coverage ratio		1.00
Debt covenant, availability of line of credit		10.00%
Debt covenant, availability of line of credit, amount		$ 4,000,000
Revolving Credit Agreement \| Revolving Credit Facility \| Subsequent Event
Debt Instrument [Line Items]
Revolving line of credit					$ 40,000,000

Debt

9 Months Ended

Feb. 25, 2024

Debt Disclosure [Abstract]

Debt

Long-term debt, net consists of the following:


(In thousands)	February 25, 2024		May 28, 2023
Term loan, related party	$	153,477	$	142,503
Equipment sale finance liability, related party	7,343		7,730
Total principal amount of long-term debt	160,820		150,233
Less: unamortized debt discount	(529)		(605)
Less: debt discount, related party	(63,182)		(64,792)
Total long-term debt, net of discounts	97,109		84,836
Less: current portion of long-term debt, net, related party	(773)		(580)
Long-term debt, net	$	96,336	$	84,256

The future minimum principal payments of the Company’s term loan and equipment sale finance liability for each year presented are as follows (in thousands), excluding forecasted cash and PIK interest:


Remainder of Fiscal year 2024	$	193
Fiscal year 2025	773
Fiscal year 2026	773
Fiscal year 2027	773
Fiscal year 2028	773
Thereafter	157,535
Total	$	160,820

Term Loan Credit Facility

On May 22, 2023, Company, Curation and Lifecore Biomedical Operating Company, Inc. (together with the Company and Curation, the “Borrowers”) and Alcon entered into a Credit and Guaranty Agreement (the “Term Loan Credit Facility”). The Term Loan Credit Facility refinanced in full all obligations of the Company and their subsidiaries under its prior term loan credit facility. Upon entry into the Term Loan Credit Facility, the prior term loan credit facility was terminated and all noncompliance with debt covenants were thereby cured.

The Term Loan Credit Facility provides for up to $142.3 million in term loans, subject to certain adjustments based on the post-closing adjustments to the Purchase Price (as defined in the Equipment Sale and Leaseback Agreement, defined below), which were funded in full on May 22, 2023. The obligations under the Term Loan Credit Facility mature on May 22, 2029. The Term Loan Credit Facility is secured by the same collateral that secures the Revolving Credit Facility (as defined below), with relative priorities in respect thereof, as set forth in the Intercreditor Agreement (as defined below).

The Company had unamortized debt discount amounting to $63.7 million and $65.4 million as of February 25, 2024 and May 28, 2023, respectively, related to the Term Loan Credit Facility, which are recorded as a reduction of the term loan liability in the Condensed Consolidated Balance Sheets.

The Company identified a number of embedded derivatives that require bifurcation from the Term Loan Credit Facility that were separately accounted for in the condensed consolidated financial statements as one compound derivative liability. Certain of these embedded features include change in control provisions, events of default and contingent rate increases and were determined to qualify as an embedded derivative under ASC 815-40. The embedded derivative is classified as a Level 3 financial liability in the fair value hierarchy as of May 28, 2023. The fair value of the embedded derivative liabilities associated with the term loans was estimated using the discounted cash flow method under the income approach. This involves significant Level 3 inputs and assumptions including an estimated probability and timing of a change in control and events of default. The Company will re-evaluate this assessment each reporting period and records any gains or losses in other income (expense). The initial recognition of the embedded derivative liability upon issuance of the Term Loan Credit Facility on May 22, 2023 was $64.9 million and is recorded as a debt derivative liability, related party in the condensed Consolidated Balance Sheets. The bifurcation of the embedded debt derivative fair value of $64.9 million is accounted for as a discount to the Term Loan Credit Facility. Amortization of the debt discount is based on the effective interest method over the term of the debt. At February 25, 2024 and May 28, 2023, the fair value of the embedded derivative liability approximated $23.0 million and $64.9 million, respectively.

As of February 25, 2024 and May 28, 2023, the Company had $153.5 million and $142.5 million in borrowings outstanding under the Term Loan Credit Facility, at an effective annual interest rate of 10.0% and 10.0%, respectively.

As of February 25, 2024 and May 28, 2023, except for the requirements to deliver certain historical financial statements, the Company was in compliance with all financial covenants under the Term Loan Credit Facility and Revolving Credit Facility (as discussed below). In December 2023, the Company entered into limited waivers and amendments to credit agreements; refer to Note 9 – Subsequent Events for additional information.

Pledge and Security Agreement

Also on May 22, 2023, the Borrowers and certain of the Company’s other subsidiaries, as grantors (collectively, the “Grantors”), entered into a Pledge and Security Agreement (the “Term Loan Security Agreement”), dated as of May 22, 2023, with Alcon, as collateral agent. Pursuant to the Term Loan Security Agreement, the Grantors secured their obligations under the Term Loan Credit Facility by granting to Alcon a first priority security interest in certain collateral, including but not limited to equipment, fixtures, real property and intellectual property of the Company. The security interest granted by the Grantors under the Term Loan Security Agreement continues in effect until the payment in full of all of the secured obligations under the Term Loan Credit Facility.

Amendment to Revolving Credit Facility

On May 22, 2023, the Borrowers and certain of the Company’s other subsidiaries, as guarantors, entered into a Limited Waiver, Consent and Fifth Amendment (the “Revolving Loan Amendment”) to the credit agreement with BMO Harris Bank, N.A. (“BMO”), as lender (the “Revolving Credit Facility”).

The Revolving Loan Amendment provides for, among other things, (i) a waiver of all known existing defaults under the Revolving Credit Facility as of the date of the Revolving Loan Amendment, (ii) the reduction of the maximum amount available under the Revolving Credit Facility to up to the lesser of (x) $40.0 million, less a reserve for certain secured credit products, if any, and (y) the borrowing base (which, pursuant to the Revolving Loan Amendment, was modified to include a further reduction of the borrowing base by an additional $4.0 million), (iii) the modification of the springing minimum fixed charge coverage ratio of 1.00 to 1.00, with such covenant not tested until the fiscal quarter ending on or about February 28, 2024 and, on or thereafter, upon the earlier of the occurrence of an event of default or availability being less than the greater of 10% of the maximum borrowing amount and $4.0 million, (iv) cash dominion at all times that the Revolving Credit Facility remains outstanding, and (v) certain other revisions to align with the terms of the Term Loan Credit Facility and address the relative priorities and credit for borrowings related to the Company’s commercial relationships with Alcon.

The Company records its Revolving Credit Facility deferred finance costs as an asset; as such, $1.7 million were recorded as other assets in the accompanying Condensed Consolidated Balance Sheet as of February 25, 2024. As of May 28, 2023, $0.9 million and $1.4 million were recorded as other current assets and other long-term assets, respectively.

As of February 25, 2024 and May 28, 2023, the Company had $19.9 million and $16.8 million, respectively, in borrowings outstanding under the Revolving Credit Facility, at an effective annual interest rate of 8.15% and 12.16%, respectively.

As of February 25, 2024, we had approximately $5.7 million available for borrowing under our revolving credit facility.

BMO and Alcon also entered into an Intercreditor agreement regarding their relative rights, as lenders, in the assets of the Company and its subsidiaries that serve as collateral for their respective credit facilities (the “Intercreditor Agreement”).

Amended and Restated Contract Manufacturing Agreement

On December 31, 2023, the Company entered into an Amended and Restated Contract Manufacturing Agreement (the “Amended and Restated CMA”), with Alcon, which amended and restated the existing contract manufacturing agreement between the Company and Alcon related to the Company’s aseptic manufacturing of a variety of ophthalmic viscoelastic injection devices.

The initial term of the Amended and Restated CMA expires December 31, 2031, subject to earlier termination by Alcon under certain circumstances or by either party for a material breach by the other party that is not cured after notice and an opportunity to cure.

The Amended and Restated CMA contains terms and provisions customary for transactions of this type, including forecast and purchase order procedures, prices that are subject to annual index-based adjustments, minimum purchase obligations, on-time-in-full service level metrics and remedies, product warranties and confidentiality and indemnification obligations. In the event the Company is unable to meet specified metrics pursuant to the Amended and Restated CMA, under certain circumstances, Alcon will be entitled to certain financial concessions, as well as certain rights and documents with respect to Alcon purchase orders until applicable metrics are met.

On May 2, 2024, the Company entered into an amendment to the Amended and Restated CMA, in which the lender made a prepayment in the amount of $5.5 million in cash as an advance on future purchases. Under the terms, the lender is entitled to apply the prepayment towards invoices issued by the Company within the scope of the agreement during calendar year 2026.

Limited Waivers and Amendments to Credit Agreements

On December 31, 2023, the Company entered into (i) a Limited Waiver and First Amendment to Credit and Guaranty Agreement (the “Alcon Amendment”), with Alcon, which amended the Term Loan Credit Facility, and (ii) the Limited Waiver and Sixth Amendment to Credit Agreement (the “BMO Amendment” and, together with the Alcon Amendment, the “Credit Agreement Amendments”) which amended the Revolving Credit Facility.

The Alcon Amendment provides for, among other things, (i) a waiver of the specified defaults listed therein under the Term Loan Credit Facility as of the date of the Alcon Amendment, (ii) a waiver of the requirement to deliver certain historical financial statements, (iii) the inclusion of a requirement that the Company notify Alcon in advance of any layoff(s) by the Company and/or its subsidiaries that would result in a reduction in the overall headcount of the Company’s full-time manufacturing and support personnel by more than 20 persons in the aggregate, and (iv) an amendment to the financial reporting requirements under the Term Loan Credit Facility providing additional time for the Company’s delivery of its financials for the quarter ended November 26, 2023.

The BMO Amendment provides for, among other things, (i) a waiver of the specified defaults listed therein under the Revolving Credit Facility as of the date of the BMO Amendment, (ii) a waiver of the requirement to deliver certain historical financial statements, (iii) an amendment to the definition of “Applicable Margin” with respect to loans under the Revolving Credit Facility from December 31, 2023 until the “Specified Adjustment Date” (as defined in the Revolving Credit Facility as amended by the BMO Amendment) (i.e., the date on which 2024 audited annual financial statements and certain other materials are delivered by the Company to BMO), and (iv) an amendment to the definition of “Eligible Accounts” thereunder in respect of certain accounts.

The Company was not required to pay any fees in connection with the Credit Agreement Amendments.

Equipment Sale and Leaseback Agreements

On May 22, 2023, the Company entered into an Equipment Sale and Leaseback Agreement (the “Equipment Sale and Leaseback Agreement”), with Alcon, wherein the Company sold $10.0 million (the “Purchase Price”), subject to certain post-closing adjustments of certain equipment, machinery, and other property associated with the production of sodium hyaluronate

(the “Equipment”) to Alcon. The Equipment Sale Leaseback Agreement contains an option for the Company to repurchase the Equipment upon the earlier of (i) seven (7) years and (ii) the expansion of the Company’s existing production capacity with respect to sodium hyaluronate, for a purchase price equal to the Purchase Price, less the aggregate of all Paydown Payments (as defined in the Equipment Lease Agreement). The Purchase Price was subsequently reduced to $7.7 million based on the fair value of the Equipment, as required by the terms of the Equipment Sale and Leaseback Agreement. The difference of $2.3 million between the initial sales value of $10.0 million and the $7.7 million was added to the term loan agreement, which resulted in a term loan amount of $142.3 million and the proceeds to Lifecore across the two agreements did not change.

Concurrently with the entry into the Equipment Sale and Leaseback Agreement, the Company entered into an Equipment Lease Agreement (the “Equipment Lease Agreement” and, together with the Equipment Sale Leaseback Agreement, the Term Loan Credit Facility, the Term Loan Security Agreement, and the Revolving Loan Amendment, collectively, the “Refinancing Transactions”), dated May 22, 2023, with Alcon, wherein Alcon leased the equipment back to the Company. The Equipment Lease Agreement expires upon the earlier of (i) May 22, 2033, and (ii) the date that the equipment is repurchased by the Company pursuant to the terms of the Equipment Lease Agreement. Upon the expiration of the Equipment Lease Agreement, the Company shall automatically repurchase the equipment for $1.00 (if not previously repurchased pursuant to the option under the Equipment Sale and Leaseback Agreement).

During the lease term, the Company is obligated to make quarterly rental payments to Alcon equal to (i) 1/40th of the Purchase Price (the “Paydown Payments”), plus (ii) 1.5% times the Purchase Price less cumulative Paydown Payments made. The Company concluded that the Equipment Sale and Leaseback Agreement did not meet the requirements for sale-leaseback accounting, therefore the carrying value of the Equipment remains on the Condensed Consolidated Balance Sheets and the $7.7 million Purchase Price (as adjusted) of the equipment sale finance obligation (the “Equipment Sale Finance Liability”) was classified in Long-term debt, net.

The Equipment Lease Agreement contains terms and provisions (including representations, covenants, and conditions) that are generally customary for a commercial lease of this nature, including obligations relating to the use, operation, and maintenance of the equipment. During the term of the lease, Alcon is not permitted to sell or encumber the equipment. Alcon is only entitled to cancel the Equipment Lease Agreement in the event of insolvency, liquidation or bankruptcy, and its remedies for other breaches of the Equipment Lease Agreement are otherwise limited to monetary damages.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

Subsequent Events	9 Months Ended
Subsequent Events	Feb. 25, 2024
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events Amended and Restated Contract Manufacturing Agreement On May 2, 2024, the Company entered into an amendment to the Amended and Restated CMA, in which the lender made a prepayment in the amount of $5.5 million in cash as an advance on future purchases. Under the terms, the lender is entitled to apply the prepayment towards invoices issued by the Company within the scope of the agreement during calendar year 2026. Lender Updates On May 10, 2024, the Company also entered into the Seventh Amendment to the ABL Loan Agreement with its ABL lender to execute a “first-in, last-out” tranche of revolving loans under the ABL Loan Agreement (the “FILO Amendment”). While not increasing the overall revolver commitment of $40 million, the FILO Amendment provides for up to approximately $2.5 million of incremental revolving loan capacity to the Company, subject to a variable cap, without changing the collateral. In connection with the FILO Amendment, the margin rate applicable to the borrowings pursuant to the FILO Amendment was increased to SOFR plus 4.25%, which is expected to increase annual cash interest expense by approximately $44,000 assuming $2.5 million in FILO tranche borrowings thereunder. The maximum capacity of permitted borrowings pursuant to the FILO Amendment will be reduced on a monthly basis commencing October 1, 2025. The Company paid a fee of $50,000 to BMO in connection with the FILO Amendment. Assignment for the Benefit of Creditors On May 15, 2024, the Company, as the sole stockholder of Curation, and Curation, as the sole stockholder of each of Camden Fruit Corp. (“Camden”) and Greenline Logistics, Inc. (“Greenline” and, together with Curation and Camden, the “Assignors”), and the board of directors and shareholders of each of the Assignors, determined that it is in the best interests of each of the Assignors and their respective stakeholders, as applicable, to effect a transfer and assignment of substantially all of each of the Assignors assets to SG Service Co., LLC (the “Assignee”) for liquidation and distribution to the creditors of each of the Assignors (the “Assignment”). The Assignment will be effectuated pursuant to that certain General Assignment, by and among the Assignors and the Assignee, and related documentation, pursuant to which all of the Assignors’ currently existing right, title, and interest in all real or personal property and all other assets, whatsoever and wheresoever situated will be assigned, granted, conveyed and transferred to the Assignee, in trust. The Assignee will then liquidate the assets for the general benefit of the Assignors’ respective creditors according to their respective priorities at law to satisfy the Assignors’ obligations. Upon the completion of the Assignment, the Assignee will have sole control over the Assignors’ assets and the Assignors will no longer control the liquidation or distribution of their assets or the resolution of any creditor claims. Shareholder Cooperation Agreements On June 28, 2024, the Company entered into cooperation agreements (the “Cooperation Agreements”) with each of (i) the 22NW Investor Group, (ii) the Legion Investor Group, and (iii) the Wynnefield Investor Group, as defined in the respective Cooperation Agreement. Pursuant to the terms of the Cooperation Agreements, the Company, the 22NW Investor Group, the Legion Investor Group, and the Wynnefield Investor Group agreed to take certain actions with respect to board composition matters and agreed to certain customary standstill provisions. In connection with the Cooperation Agreements, the Company accrued $0.4 million in expenses during fiscal year 2024 and has estimated to incur an additional $1.5 million in costs during the first quarter of 2025, and which are expected to be paid during the second quarter of 2025. Reduction in Workforce On July 8, 2024, the Company determined to implement a strategic reduction of the Company’s workforce (the “Workforce Reduction Plan”) to terminate 46 full-time employees of the Company, representing approximately 9% of the Company’s workforce, as part of an initiative to strategically optimize the Company’s cost structure. In connection with the Workforce Reduction Plan, the Company estimates that it will incur termination benefit costs of approximately $1.0 million, which primarily consist of one-time severance benefits. These costs are expected to be incurred in the first quarter of fiscal 2025 and paid during both the first and second quarters of fiscal 2025. Class Action Complaint On July 29, 2024, a putative class action complaint was filed on behalf of shareholders of the Company in the United States District Court of Minnesota against the Company and certain of its named executive officers. The complaint generally alleges that statements made to the Company’s shareholders between October 7, 2020, and March 19, 2024 regarding the Company’s financial results, internal controls, remediation efforts, periodic reporting, and financial prospects were false and misleading in violation of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the individual defendants are liable for such statements because they are controlling persons under Section 20(a) of the Exchange Act. The complaint seeks compensatory damages, court costs, and attorneys’ fees. The Company believes that the claims are without merit and intends to vigorously defend against them. Any potential loss arising from this claim is not currently probable or estimable. Amended Lease Agreement On August 9, 2024,the Company amended its lease agreement dated September, 3, 2015 with 1245, LLP, as lessor, related to office, manufacturing and warehouse space at 1245 Lakeview Drive in Chaska, MN. The primary terms of the amended lease agreement provide for approximately $2.4 million in cash to the Company in exchange for a revised rent payment schedule and an updated purchase option.

Stock-based Compensation and Stockholders' Equity

9 Months Ended

Feb. 25, 2024

Share-Based Payment Arrangement [Abstract]

Stock-based Compensation and Stockholders' Equity

Stock-based Compensation and Stockholders’ Equity

Stock-Based Compensation Activity

A summary of the activity under the Company’s stock option plans as of February 25, 2024 and changes during the fiscal year then ended is presented below:


	Options Outstanding	Weighted-Average Exercise Price Per Share		Total Intrinsic Value of Options Exercised (in thousands)		Weighted-Average Remaining Contractual Term (in Years)	Aggregate Intrinsic Value
Options outstanding at May 28, 2023	2,374,325	$	10.88
Options granted	6,300	$	7.51
Options exercised	(95,800)	$	9.38	$	115

Options expired	(119,850)	$	11.79
Options outstanding at February 25, 2024	2,164,975	$	10.88			1.21	$	—
Options exercisable at February 25, 2024	1,712,287	$	10.95			1.90	$	—

A summary of the Company’s restricted stock unit (“RSU”) award activity as of February 25, 2024 and changes during the fiscal year then ended is presented below:


	Restricted Stock Units Outstanding	Weighted-Average Grant Date Fair Value Per Share
Restricted stock units outstanding at May 28, 2023	336,791	$	9.70
Granted	1,058,556	$	8.25
Vested	(155,942)	$	8.03

Restricted stock units outstanding at February 25, 2024	1,239,405	$	8.67

Stock-Based Compensation Expense

The following table summarizes stock-based compensation by income statement line item:


	Three Months Ended				Nine Months Ended
(In thousands)	February 25, 2024		February 26, 2023		February 25, 2024		February 26, 2023
Continuing operations:
Cost of product sales	$	187	$	109	549		$	307
Research and development	42		31		126		173
Selling, general and administrative	1,265		763		3,928		2,316


Total stock-based compensation	$	1,494	$	903	$	4,603	$	2,796

As of February 25, 2024, there was $11.4 million of total unrecognized compensation expense related to unvested equity compensation awards granted under the Lifecore incentive stock plans. Total expense is expected to be recognized over the weighted-average period of 1.21 years for stock options and 1.90 years for RSUs.

Debt (Tables)

9 Months Ended

Feb. 25, 2024

Debt Disclosure [Abstract]

Schedule of Long-term Debt Instruments

Long-term debt, net consists of the following:


(In thousands)	February 25, 2024		May 28, 2023
Term loan, related party	$	153,477	$	142,503
Equipment sale finance liability, related party	7,343		7,730
Total principal amount of long-term debt	160,820		150,233
Less: unamortized debt discount	(529)		(605)
Less: debt discount, related party	(63,182)		(64,792)
Total long-term debt, net of discounts	97,109		84,836
Less: current portion of long-term debt, net, related party	(773)		(580)
Long-term debt, net	$	96,336	$	84,256

Schedule of Maturities of Long-Term Debt


Remainder of Fiscal year 2024	$	193
Fiscal year 2025	773
Fiscal year 2026	773
Fiscal year 2027	773
Fiscal year 2028	773
Thereafter	157,535
Total	$	160,820

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22))
-SubTopic 10
-Topic 210
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477734/942-470-50-3

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-6

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-7

+ Details

Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Thousands	Feb. 25, 2024	May 28, 2023
Debt Instrument [Line Items]
Total principal amount of long-term debt	$ 160,820	$ 150,233
Total long-term debt, net of discounts	97,109	84,836
Less: current portion of long-term debt, net, related party	(773)	(580)
Long-term debt, net	96,336	84,256
Nonrelated Party
Debt Instrument [Line Items]
Less: unamortized debt discount	(529)	(605)
Related Party
Debt Instrument [Line Items]
Less: unamortized debt discount	(63,182)	(64,792)
Equipment sale finance liability, related party
Debt Instrument [Line Items]
Total principal amount of long-term debt	7,343	7,730
Term Loan \| Line of Credit
Debt Instrument [Line Items]
Total principal amount of long-term debt	$ 153,477	$ 142,503

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) (Parenthetical) $ in Thousands	9 Months Ended
	Feb. 26, 2023 USD ($)
Income Statement [Abstract]
Change in net unrealized gains (losses) on interest rate swap, tax	$ 16

Stock-based Compensation and Stockholders’ Equity - Stock Options Activity (Details)	9 Months Ended
	Feb. 25, 2024 USD ($) $ / shares shares
Options Outstanding
Options outstanding, beginning balance (in shares) \| shares	2,374,325
Options granted (in shares) \| shares	6,300
Options exercised (in shares) \| shares	(95,800)
Options expired (in shares) \| shares	(119,850)
Options outstanding, ending balance (in shares) \| shares	2,164,975
Options exercisable (in shares) \| shares	1,712,287
Weighted-Average Exercise Price Per Share
Options outstanding, beginning balance (in dollars per share) \| $ / shares	$ 10.88
Options granted (in dollars per share) \| $ / shares	7.51
Options exercised (in dollars per share) \| $ / shares	9.38
Options expires (in dollars per share) \| $ / shares	11.79
Options outstanding, ending balance (in dollars per share) \| $ / shares	10.88
Options exercisable (in dollars per share) \| $ / shares	$ 10.95
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]
Total Intrinsic Value of Options Exercised (in thousands) \| $	$ 115,000
Weighted average remaining contractual term, options outstanding	1 year 2 months 15 days
Weighted average remaining contractual term, options exercisable	1 year 10 months 24 days
Aggregate intrinsic value, options outstanding \| $	$ 0
Aggregate intrinsic value, options exercisable \| $	$ 0

Debt - Future Minimum Principal Payments of Debt (Details) - USD ($) $ in Thousands	Feb. 25, 2024	May 28, 2023
Debt Disclosure [Abstract]
Remainder of Fiscal year 2024	$ 193
Fiscal year 2025	773
Fiscal year 2026	773
Fiscal year 2027	773
Fiscal year 2028	773
Thereafter	157,535
Total	$ 160,820	$ 150,233

Organization, Basis of Presentation, and Summary of Significant Accounting Policies

9 Months Ended

Feb. 25, 2024

Accounting Policies [Abstract]

Organization, Basis of Presentation, and Summary of Significant Accounting Policies

Organization

Lifecore Biomedical, Inc. and its subsidiaries (“Lifecore” or the “Company”) is a fully integrated contract development and manufacturing organization (“CDMO”) that offers capabilities in the development, fill and finish of complex sterile injectable pharmaceutical products in syringes and vials. The Company previously operated a natural food company, through its wholly-owned subsidiary, Curation Foods, Inc. (“Curation”), which was previously focused on the distribution of plant-based foods to retail, club, and food service channels throughout North America. However, upon the sale of the Divested Businesses (as defined below), the Company has ceased to operate the Curation foods business.

Discontinued Operations

During the year ended May 28, 2023, the Company entered into agreements for the sale or disposition of its subsidiaries within the Curation business (a former segment), specifically O Olive Oil and Vinegar® (“O Olive”), Yucatan Foods, LLC (“Yucatan”), and BreatheWay® (“BreatheWay”, and together with O Olive, Yucatan, and BreatheWay, the “Divested Businesses”). The Company completed the disposition of Yucatan and O Olive on February 7, 2023 and April 6, 2023, respectively.

On June 2, 2022, the Company and Curation entered into and closed an Asset Purchase Agreement (the “BreatheWay Purchase Agreement”) with Hazel Technologies, Inc. (the “BreatheWay Purchaser”), pursuant to which Curation sold all of its assets related to BreatheWay packaging technology business to the BreatheWay Purchaser in exchange for an aggregate purchase price of $3.2 million (the “BreatheWay Disposition”). The BreatheWay Purchase Agreement included various representations, warranties, and covenants of the parties generally customary for a transaction of this nature. In connection with the BreatheWay Disposition, the Company received net proceeds of $3.1 million and recorded a gain of $2.1 million in the Condensed Consolidated Statements of Operations for the three and nine months ended February 26, 2023.

The accounting requirements for reporting the Divested Businesses, excluding BreatheWay, as discontinued operations were met on the closing date of each of the divestitures. The BreatheWay Disposition met the requirements for reporting the businesses as assets held for sale in the fourth quarter of fiscal year 2022. Accordingly, the unaudited condensed consolidated financial statements and related condensed notes reflect the results of the Divested Businesses, as discontinued operations for the periods presented. Refer to Note 8 – Discontinued Operations.

Basis of Presentation

The accompanying Condensed Consolidated Balance Sheet as of May 28, 2023, which has been derived from audited financial statements, and the accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring accruals) have been made which are necessary to present fairly the financial position of the Company at February 25, 2024, and the results of operations and cash flows for all periods presented. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements and related footnotes prepared following GAAP have been condensed or omitted per the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying financial data should be reviewed in conjunction with the audited financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 28, 2023 (the “2023 Annual Report”). The Company restated its unaudited quarterly financial statements as of and for the three and nine months ended February 26, 2023 (the “Restatement”). Such restated and unaudited quarterly financial statements and related impacted amounts were presented in the Company’s Annual Report on Form 10-K for the year ended May 28, 2023. The discussion of financial results presented in this quarterly report on Form 10-Q reflects such restated amounts.

The Company’s fiscal year is the 52- or 53-week period that ends on the last Sunday of May with quarters within each year ending on the last Sunday of August, November, and February; however, in instances where the last Sunday would result in a quarter being 12-weeks in length, the Company’s policy is to extend that quarter to the following Sunday. A 14th week is included in the fiscal year every five or six years to realign the Company’s fiscal quarters with calendar quarters.

The results reported in these interim condensed consolidated financial statements are not necessarily indicative of the results that may be reported for the entire year.

As result of the Company exiting all previous food related business as part of the strategic shift in the Company’s operations that was completed as of May 28, 2023, commencing with this Quarterly Report on Form 10-Q, the Company changed its presentation of “Product sales” and “Cost of product sales” to “Revenues” and “Cost of goods sold”, respectively.

Basis of Consolidation

The condensed consolidated financial statements are presented on the accrual basis of accounting in accordance with GAAP and include the accounts of the Company and its subsidiaries. All material inter-company transactions and balances have been eliminated.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; loss contingencies; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite-lived assets (including intangible assets and goodwill), and inventory; the valuation and recognition of stock-based compensation, and the valuation of the debt derivative liability.

These estimates involve the consideration of complex factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and are subject to change from period to period. The actual results may differ from management’s estimates.

Concentrations of Risk

Cash and cash equivalents and trade accounts receivable are financial instruments that potentially subject the Company to concentrations of credit risk. Our Company policy limits, among other things, the amount of credit exposure to any one issuer and to any one type of investment, other than securities issued or guaranteed by the U.S. government. The Company maintains cash in U.S. bank accounts, the balance of which may at times exceed the federally insured limit.

During the three months ended February 25, 2024 and February 26, 2023, the Company had sales concentrations of 10% or greater from two customers, accounting for 52% and 15%, and 52% and 14% respectively.

During the nine months ended February 25, 2024, the Company had sales concentrations of 10% or greater from three customers, accounting for 40%, 19%, and 10%. During the nine months ended February 26, 2023, the Company had sales concentrations of 10% or greater from two customers, accounting for 40% and 16%.

Three of the Company’s customers had accounts receivable concentrations of 10% or greater, accounting for 38%, 14%, and 13% of accounts receivable as of February 25, 2024. Two of the Company’s customers had accounts receivable concentrations of 10% or greater, accounting for 31% and 18%, of accounts receivable as of May 28, 2023.

Contract Assets and Liabilities

Contract assets primarily relate to the Company’s unconditional right to consideration for work completed but not billed at the reporting date. The Company’s contract assets as of February 25, 2024, May 28, 2023 and May 29, 2022, were $3.4 million, $3.2 million and $10.4 million, respectively, and are included within accounts receivable in the Condensed Consolidated Balance Sheets.

Contract liabilities primarily relate to payments received from customers in advance of performance under a contract. The Company’s contract liabilities as of February 25, 2024, May 28, 2023 and May 29, 2022, were $3.5 million, $7.0 million and $0.9 million, respectively, of which $3.2 million and $4.1 million are included in deferred revenue and $0.3 million and $2.9 million are included in non-current liabilities as of February 25, 2024 and May 28, 2023, respectively, in the Condensed Consolidated Balance Sheets. Revenue recognized during the three and nine months ended February 25, 2024, that was included in the contract liability balance at the beginning of fiscal year 2024, was $1.5 million and $5.2 million, respectively.

Revenue recognized during the three and nine months ended February 26, 2023, that was included in the contract liability balance at the beginning of fiscal year 2023, was $0.1 million and $0.5 million, respectively.

Revenue Recognition

The following tables disaggregates revenue by major product lines and services (in thousands):


	Three Months Ended				Nine Months Ended
(In thousands)	February 25, 2024		February 26, 2023		February 25, 2024		February 26, 2023
Contact development and manufacturing organization	$	22,306	$	18,015	$	67,522	$	52,488
HA manufacturing	13,398		8,521		22,853		19,635

Total	$	35,704	$	26,536	$	90,375	$	72,123

Development services revenues recognized over time were $7.0 million and $9.0 million for the three months ended February 25, 2024 and February 26, 2023, respectively, and $19.2 million and $22.3 million for the nine months ended February 25, 2024 and February 26, 2023, respectively, and are included in contract development and manufacturing organization.

Revenues recognized at a point in time were $28.7 million and $17.5 million for the three months ended February 25, 2024 and February 26, 2023, respectively, and $71.1 million and $49.8 million for the nine months ended February 25, 2024 and February 26, 2023, respectively.

The Company identified certain elements of its agreements with customers for development services in which the Company is the principal in those contracts, therefore it recognizes revenues on a gross basis. For other contracts in which the Company operates as an agent, the Company recognized revenue on a net basis.

Amended and Restated Supply Agreement

On December 22, 2023, the Company entered into an amendment and restatement of a supply agreement with one of its customers (the “Amended Supply Agreement”). The key provisions of the Amended Supply Agreement included an extension of the agreement’s term for certain products through March 31, 2024, revised pricing for certain product purchase orders dated November 1, 2023, and the payment of a $5.0 million working capital deposit to the Company. The working capital deposit was received on December 22, 2023 and (i) may be used for any corporate purpose; (ii) will not accrue interest; and (iii) is required to be repaid, subject to certain defined provisions, upon the termination of the Amended Supply Agreement. On March 14, 2024, this agreement was amended to extend it through December 31, 2026.

Inventories, net

Inventories primarily consist of in-process and finished goods related to sterile injectable pharmaceutical products in syringes, vials and cartridges. This includes premium, pharmaceutical grade HA in bulk form as well as formulated and filled syringes, vials and cartridges for injectable products used in treating a broad spectrum of medical conditions and procedures.

As of February 25, 2024 and May 28, 2023, inventories consisted of the following (in thousands):


(In thousands)	February 25, 2024		May 28, 2023
Finished goods	$	13,113	$	13,141
Raw materials	18,686		17,735
Work in process	8,802		10,349
Inventory reserve	(931)		(384)
Total	$	39,670	$	40,841

The Company recorded adjustments of $1.1 million and $4.9 million to record inventory to its net realizable value as of February 25, 2024 and May 28, 2023, respectively.

The Company’s inventory serves as part of the collateral for certain of the Company’s debt arrangements. Refer to Note 6 – Debt for additional discussion on the Company’s debt arrangements and related collateral.

Fair Value Measurements

The Company uses fair value measurement accounting for financial assets and liabilities and for financial instruments and certain other items measured at fair value. The Company has not elected the fair value option for any of its other eligible financial assets or liabilities.

Applicable accounting guidance establishes a three-tier hierarchy for fair value measurements, which prioritizes the inputs used in measuring fair value as follows:

Level 1 – observable inputs such as quoted prices for identical instruments in active markets.

Level 2 – inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data.

Level 3 – unobservable inputs in which there is little or no market data, which would require the Company to develop its own assumptions.

Cash is stated at cost, which approximates its fair value. The carrying amounts reported in the balance sheets for accounts receivable, accounts payable and accrued liabilities approximate fair value, due to their short-term maturities.

Outstanding borrowings that qualify as financial instruments are carried at cost, which approximates their fair value as of February 25, 2024 and May 28, 2023, due to their short duration, except for the Alcon Research, LLC (“Alcon”) term debt with a fair value of $117.7 million that exceeds carrying value.

The Term Loan Credit Facility (as defined in Note 6 Note 6 – Debt) contains embedded derivatives requiring bifurcation as a derivative instrument. The derivative liability related to the Term Loan Credit Facility is recorded as a discount to the long-term debt in the Condensed Consolidated Financial Statements. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a non-operating income (expense). The fair value of the embedded derivative liabilities associated with the Term Loan Credit Facility was estimated using a probability weighted discounted cash flow model to measure the fair value. This involves significant Level 3 inputs and assumptions including (i) an estimated probability and timing of a change in control and event of default, and (ii) a risk-adjusted discount rate. At February 25, 2024 and May 28, 2023, the fair value of the embedded derivative liability approximated $23.0 million and $64.9 million, respectively.

Imprecision in estimating unobservable market inputs can affect the amount of gain or loss recorded for a particular position. The use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.

The following table summarizes the fair value of the Company’s assets and liabilities that are measured at fair value on a recurring and non-recurring basis (in thousands):


	Fair Value at February 25, 2024			Fair Value at May 28, 2023
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3








Liabilities:
Debt derivative liability(1)	—	—	23,000	—	—	64,900
Total liabilities	—	—	23,000	—	—	64,900

(1) As of February 25, 2024 and May 28, 2023, the fair value of the debt derivative liability is included in non-current liabilities in the Company’s Condensed Consolidated Balance Sheets.

The key inputs to the valuation models that were utilized to estimate the fair value of the debt derivative liability were (i) an estimated probability related to the timing of a change in control over the 12 months following the end of the fiscal period; (ii) the estimated probability related to an event of default of the Supply Agreement with Alcon, as amended, over the 12 months following the end of the fiscal period; and (iii) a risk-adjusted discount rate. Beginning in the second quarter of fiscal year 2024 and continuing through the third quarter of fiscal year 2024, there were sequential declines in the change in control probabilities assumptions in connection with the Company’s review of the strategic alternatives initiative that significantly impacted the fair value of the debt derivative liability. There was no change in the probability related to event of default of the supply agreement during fiscal year 2024.

The risk adjusted discount rate as of February 25, 2024 and May 28, 2023, were as follows:


	February 25, 2024	May 28, 2023
Assumptions
Discount rate	21.3% — 24.2%	22.3% — 24.5%
Implied spread	17.0%	18.5%
Risk free rate	4.3% — 7.2%	3.8% — 6.0%

The following table reflects the fair value roll forward reconciliation of Level 3 assets and liabilities measured at fair value for the nine months ended February 25, 2024 (in thousands):


	Debt Derivative Liability
Balance as of May 29, 2022	$	—
Fair value on issuance(1)	$	64,900
Balance as of May 28, 2023	64,900
Decrease in fair value(2)	(41,900)
Balance as of February 25, 2024	$	23,000

(1)At May 28, 2023, the fair value of the embedded derivative liability approximated the fair value upon issuance on May 22, 2023.

(2)For the nine months ended February 25, 2024, the decrease in fair value is recorded within “Change in fair value of debt derivative liability, related party” within the condensed consolidated statement of operations.

Related Party Transactions

The Company has reflected the related party balances on the face of its financial statements beginning in the period which Alcon became a related party, which was as of May 22, 2023 at the time Alcon provided financing to the Company. Prior to providing financing, and continuing subsequently, Alcon was a customer of the Company. Refer to Note 6 – Debt for additional discussion on the Company’s debt agreement with Alcon.

Commitments and Contingencies

Legal Contingencies

In the ordinary course of business, the Company is involved in various legal proceedings and claims.

The Company makes a provision for a liability relating to legal matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These provisions are reviewed at least each fiscal quarter and adjusted to reflect the impacts of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. Legal fees are expensed in the period in which they are incurred.

Confidential Settlement Agreement and Release

On August 24, 2023, the Company reached a confidential settlement and release agreement with a third-party insurance underwriter. In connection with this settlement agreement, the Company received a cash payment of $1.9 million on September 19, 2023.

Landlord Complaints

On January 12, 2024, the landlord for a property leased by Curation filed a complaint of unlawful detainer against the Company in Santa Barbara County Superior Court, seeking possession of the building and alleging past due rent of approximately $0.2 million. The Company has accrued past due rents, but the ultimate exposure to loss will depend on future events and is not reasonably certain at this time.

On January 12, 2024, a landlord for a different property leased by Curation delivered to the Company a pay or quit notice related to such property, seeking payment of past due rent of approximately $0.1 million or requesting Curation to vacate the property. The Company has accrued past due rents, but the ultimate exposure to loss will depend on future events and is not reasonably certain at this time.

Settlement of a Supplier Note Receivable

In February 2024, the Company received approximately $0.9 million in settlement of a note receivable from a former supplier to a divested business (the “Note”). The Company had treated this settlement as a gain contingency, as the original aggregate amount of the Note was written off in a previous period; therefore, it was accounted for during the third quarter of fiscal year 2024 when the payment was received.

SEC Subpoena

On February 16, 2024, the Chicago Regional Office of the SEC has issued a subpoena to the Company seeking documents and information concerning the Restatement. The Company is in the process of responding to the subpoena and intends to cooperate with the SEC. We cannot predict the duration or outcome of this matter at this time.

Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board issued new guidance on income tax disclosures (ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”). Among other requirements, this update adds specific disclosure requirements for income taxes, including: (1) disclosing specific categories in the rate reconciliation and (2) providing additional information for reconciling items that meet quantitative thresholds. The guidance is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the impact of the adoption of ASU 2023-09 on the Company’s condensed consolidated financial statements and disclosures.

In November 2023, the FASB issued new guidance on segment reporting (ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”). The amendments in the ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is in the process of evaluating the impact of the adoption of ASU 2023-07 on the Company’s condensed consolidated financial statements and disclosures.

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Feb. 25, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (Unaudited) - USD ($) shares in Thousands	3 Months Ended		9 Months Ended
	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024	Feb. 26, 2023
Revenues	$ 35,704,000	$ 26,536,000	$ 90,375,000	$ 72,123,000
Cost of goods sold	23,810,000	17,988,000	65,797,000	51,917,000
Gross profit	11,894,000	8,548,000	24,578,000	20,206,000
Operating costs and expenses:
Research and development	2,170,000	2,234,000	6,414,000	6,621,000
Selling, general and administrative	9,848,000	10,279,000	28,239,000	26,675,000
Restructuring costs	771,000	2,566,000	918,000	4,176,000
Total operating costs and expenses	12,789,000	15,079,000	35,571,000	35,364,000
Operating loss	(895,000)	(6,531,000)	(10,993,000)	(15,158,000)
Change in fair value of debt derivative liability, related party	21,000,000	0	41,900,000	0
Other income (expense), net	(814,000)	104,000	(1,950,000)	(330,000)
Net income (loss) from continuing operations before taxes	15,002,000	(11,260,000)	16,657,000	(27,160,000)
Provision for income tax expense	(217,000)	(70,000)	(240,000)	(78,000)
Net income (loss) from continuing operations	14,785,000	(11,330,000)	16,417,000	(27,238,000)
Discontinued operations:
Income (loss) from discontinued operations before taxes	850,000	(25,177,000)	2,700,000	(33,041,000)
Income tax (expense) benefit	(3,000)	0	(21,000)	0
Income (loss) from discontinued operations, net of tax	847,000	(25,177,000)	2,679,000	(33,041,000)
Net income (loss)	$ 15,632,000	$ (36,507,000)	$ 19,096,000	$ (60,279,000)
Basic net income (loss) per share:
Income (loss) from continuing operations (in dollars per share)	$ 0.48	$ (0.37)	$ 0.54	$ (0.91)
Loss from discontinued operations (in dollars per share)	0.03	(0.83)	0.09	(1.11)
Total basic net income (loss) per share (in dollars per share)	0.51	(1.20)	0.63	(2.02)
Diluted net income (loss) per share:
Income (loss) from continuing operations (in dollars per share)	0.40	(0.37)	0.45	(0.91)
Loss from discontinued operations (in dollars per share)	0.02	(0.83)	0.07	(1.11)
Total diluted net income (loss) per share (in dollars per share)	$ 0.42	$ (1.20)	$ 0.52	$ (2.02)
Shares used in per share computation:
Basic (in shares)	30,488	30,304	30,450	29,838
Diluted (in shares)	36,609	30,304	36,469	29,838
Other comprehensive income (loss), net of tax:
Net income (loss)	$ 15,632,000	$ (36,507,000)	$ 19,096,000	$ (60,279,000)
Net unrealized gain on interest rate swaps (net of tax effect of $16)	0	0	0	586,000
Total comprehensive income (loss)	15,632,000	(36,507,000)	19,096,000	(59,693,000)
Nonrelated Party
Revenues	17,054,000	26,536,000	54,528,000	72,123,000
Operating costs and expenses:
Interest expense, net	(921,000)	(4,833,000)	(2,546,000)	(11,672,000)
Related Party
Revenues	18,650,000	0	35,847,000	0
Operating costs and expenses:
Interest expense, net	(3,368,000)	0	(9,754,000)	0
BreatheWay
Operating costs and expenses:
Gain on sale of divested business	$ 0	$ 0	$ 0	$ (2,108,000)

Stock-based Compensation and Stockholders' Equity - Narrative (Details) $ in Millions	9 Months Ended
	Feb. 25, 2024 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 11.4
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period (in years)	1 year 2 months 15 days
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period (in years)	1 year 10 months 24 days

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Restructuring Costs

9 Months Ended

Feb. 25, 2024

Restructuring and Related Activities [Abstract]

Restructuring Costs

The following table summarizes the restructuring costs recognized in the Company’s Condensed Consolidated Statements of Operations, excluding discontinued operations, in connection with the previously announced restructuring plan.


	Three Months Ended				Nine Months Ended
(in thousands)	February 25, 2024		February 26, 2023		February 25, 2024		February 26, 2023

Employee severance and benefit costs	$	76	$	2,187	$	215	$	2,282
Lease costs	684		43		700		88
Other restructuring costs	11		336		3		1,806
Total restructuring costs	$	771	$	2,566	$	918	$	4,176

The restructuring plan has been substantially completed as of May 28, 2023. The following table summarizes the restructuring costs recognized in the Company’s Condensed Consolidated Statements of Operations since the inception of the restructuring plan in fiscal year 2020 through February 25, 2024, excluding discontinued operations:


	Total
(in thousands)
Asset write-off costs, net	$	13,893
Employee severance and benefit costs	4,314
Lease costs	4,814
Other restructuring costs	7,853
Total restructuring costs	$	30,874

The following table presents the movement of the restructuring costs liability from May 28, 2023 through February 25, 2024, excluding discontinued operations, within current liabilities in the Condensed Consolidated Balance Sheet:


(in thousands)	May 28, 2023		Expense		Payments		February 25, 2024
Employee severance and benefit costs	$	1,600	$	215	$	(1,300)	$	515
Lease costs	257		700		(128)		829
Other restructuring costs	1,140		3		(923)		220
	$	2,997	$	918	$	(2,351)	$	1,564

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Thousands	Feb. 25, 2024	Nov. 26, 2023	Aug. 27, 2023	Feb. 26, 2023	Nov. 27, 2022	Aug. 28, 2022	Feb. 25, 2024	Feb. 26, 2023
Pay vs Performance Disclosure
Net income (loss)	$ 15,632	$ 14,218	$ (10,754)	$ (36,507)	$ (12,806)	$ (10,966)	$ 19,096	$ (60,279)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 60
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 323
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1

+ Details

Organization, Basis of Presentation, and Summary of Significant Accounting Policies - Fair Value Reconciliation of Level 3 (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024	Feb. 26, 2023	May 28, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Decrease in fair value	$ (21,000)	$ 0	$ (41,900)	$ 0
Debt Derivative Liability
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance			64,900	$ 0	$ 0
Fair value on issuance					64,900
Decrease in fair value			(41,900)
Ending balance	$ 23,000		$ 23,000		$ 64,900

Discontinued Operations (Tables)

9 Months Ended

Feb. 25, 2024

Discontinued Operations and Disposal Groups [Abstract]

Disposal Groups, Including Discontinued Operations

The key components of income from discontinued operations for the three and nine months ended February 25, 2024 and February 26, 2023 were as follows (in thousands):


	Three Months Ended				Nine Months Ended
	February 25, 2024		February 26, 2023		February 25, 2024		February 26, 2023
Revenues	$	—	$	12,190	$	—	$	48,954
Cost of product sales	—		14,056		—		50,282
Gross profit	—		(1,866)		—		(1,328)
Operating costs and expenses:
Research and development	—		48		—		217
Selling, general and administrative	—		2,536		—		9,415
Impairment of intangible asset and goodwill	—		—		—		1,300
Loss on Sale of Yucatan	—		20,670		—		20,670

Restructuring costs	—		57		—		111
Total operating costs and expenses	—		23,311		—		31,713
Operating loss	—		(25,177)		—		(33,041)


Other income (expense), net	850		—		2,700		—
Income (loss) from discontinued operations before taxes	850		(25,177)		2,700		(33,041)
Income tax benefit (expense)	(3)		—		(21)		—
Income (loss) from discontinued operations, net of tax	$	847	$	(25,177)	$	2,679	$	(33,041)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-SubTopic 10
-Topic 360
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483475/205-20-45-11

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3A

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4A

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-4B

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5B

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5C

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5D

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 20
-Topic 205
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-3

+ Details

Restructuring Costs - Restructuring Costs Liability Roll-Forward (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		57 Months Ended
	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance			$ 2,997
Expense	$ 771	$ 2,566	918	$ 4,176	$ 30,874
Payments			(2,351)
Restructuring reserve, ending balance	1,564		1,564		1,564
Employee severance and benefit costs
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance			1,600
Expense	76	2,187	215	2,282	4,314
Payments			(1,300)
Restructuring reserve, ending balance	515		515		515
Lease costs
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance			257
Expense	684	43	700	88	4,814
Payments			(128)
Restructuring reserve, ending balance	829		829		829
Other restructuring costs
Restructuring Reserve [Roll Forward]
Restructuring reserve, beginning balance			1,140
Expense	11	$ 336	3	$ 1,806	7,853
Payments			(923)
Restructuring reserve, ending balance	$ 220		$ 220		$ 220

Earnings Per Share - Narrative (Details) - shares	3 Months Ended	9 Months Ended
Earnings Per Share - Narrative (Details) - shares	Feb. 26, 2023	Feb. 26, 2023
RSUs
Class of Stock [Line Items]
Amount of securities excluded from computation of earnings per share (in shares)	87,670	127,905
Stock Options
Class of Stock [Line Items]
Amount of securities excluded from computation of earnings per share (in shares)	0	0
Convertible Preferred Stock
Class of Stock [Line Items]
Amount of securities excluded from computation of earnings per share (in shares)	38,750	38,750

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 272
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(27)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-03(i)(2)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3

+ Details

Organization, Basis of Presentation, and Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands					1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 12, 2024	Dec. 22, 2023	Sep. 19, 2023	Jun. 02, 2022	Feb. 25, 2024	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024	Feb. 26, 2023	May 28, 2023	May 29, 2022
Accounting Policies [Line Items]
Deferred revenue					$ 3,500	$ 3,500		$ 3,500		$ 7,000	$ 900
Deferred revenue, current					3,200	3,200		3,200		4,100
Deferred revenues, less current portion										2,900
Revenue recognized included in the contract liability						1,500	$ 100	5,200	$ 500
Revenues						35,704	26,536	90,375	72,123
Proceeds from working capital deposit		$ 5,000						5,000	0
Inventory write-down								1,100		4,900
Received cash payment			$ 1,900
Sale of Investment in non-public company					900
Other Noncurrent Liabilities
Accounting Policies [Line Items]
Deferred revenue					300	300		300
Landlord complaint one
Accounting Policies [Line Items]
Damages sought	$ 200
Landlord complaint two
Accounting Policies [Line Items]
Damages sought	$ 100
Estimate of Fair Value Measurement
Accounting Policies [Line Items]
Borrowings, fair value					117,700	117,700		117,700
Transferred at Point in Time
Accounting Policies [Line Items]
Revenues						28,700	17,500	71,100	49,800
Contact development and manufacturing organization
Accounting Policies [Line Items]
Revenues						22,306	18,015	67,522	52,488
Contact development and manufacturing organization \| Transferred over Time
Accounting Policies [Line Items]
Revenues						7,000	$ 9,000	19,200	$ 22,300
Level 3 \| Recurring
Accounting Policies [Line Items]
Financial liabilities fair value disclosure					23,000	23,000		23,000		64,900
Unbilled Revenues
Accounting Policies [Line Items]
Contract with customer, assets					$ 3,400	$ 3,400		$ 3,400		$ 3,200	$ 10,400
Customer A \| Sales Revenue, Net \| Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk percentage						52.00%	52.00%	40.00%	40.00%
Customer A \| Accounts Receivable \| Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk percentage								38.00%		31.00%
Customer B \| Sales Revenue, Net \| Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk percentage						15.00%	14.00%	19.00%	16.00%
Customer B \| Accounts Receivable \| Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk percentage								14.00%		18.00%
Customer C \| Sales Revenue, Net \| Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk percentage								10.00%
Customer C \| Accounts Receivable \| Customer Concentration Risk
Accounting Policies [Line Items]
Concentration risk percentage								13.00%
BreatheWay
Accounting Policies [Line Items]
Proceeds from the sale of net								$ 0	$ 15,666
Discontinued Operations, Disposed of by Sale \| BreatheWay
Accounting Policies [Line Items]
Consideration for disposition				$ 3,200
Proceeds from the sale of net				$ 3,100
Gain (loss) on disposal							$ 2,100		$ 2,100

Organization, Basis of Presentation, and Summary of Significant Accounting Policies - Fair Value Measurements (Details) $ in Thousands	Feb. 25, 2024 USD ($)	May 28, 2023 USD ($)
Implied spread
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.170	0.185
Minimum \| Discount rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.213	0.223
Minimum \| Risk free rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.043	0.038
Maximum \| Discount rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.242	0.245
Maximum \| Risk free rate
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input	0.072	0.060
Level 1 \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt derivative liability	$ 0	$ 0
Total liabilities	0	0
Level 2 \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt derivative liability	0	0
Total liabilities	0	0
Level 3 \| Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt derivative liability	23,000	64,900
Total liabilities	$ 23,000	$ 64,900

Stock-based Compensation and Stockholders’ Equity - Restricted Unit Activity (Details) - Restricted Stock	9 Months Ended
	Feb. 25, 2024 $ / shares shares
Restricted Stock Units Outstanding
Beginning balance (in shares) \| shares	336,791
Granted (in shares) \| shares	1,058,556
Vested (in shares) \| shares	(155,942)
Ending balance (in shares) \| shares	1,239,405
Weighted-Average Grant Date Fair Value Per Share
Beginning balance (in dollars per share) \| $ / shares	$ 9.70
Granted (in dollars per share) \| $ / shares	8.25
Vested (in dollars per share) \| $ / shares	8.03
Ending balance (in dollars per share) \| $ / shares	$ 8.67

Organization, Basis of Presentation, and Summary of Significant Accounting Policies - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024	Feb. 26, 2023
Segment Reporting Information [Line Items]
Revenues	$ 35,704	$ 26,536	$ 90,375	$ 72,123
Contact development and manufacturing organization
Segment Reporting Information [Line Items]
Revenues	22,306	18,015	67,522	52,488
HA manufacturing
Segment Reporting Information [Line Items]
Revenues	$ 13,398	$ 8,521	$ 22,853	$ 19,635

- Definition

Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4

+ Details

Earnings Per Share (Tables)

9 Months Ended

Feb. 25, 2024

Earnings Per Share [Abstract]

Schedule of Computation of Diluted Net Income Per Share

The following table sets forth the computation of basic and diluted earnings per share:


	Three Months Ended				Nine Months Ended
(In thousands, except per share amounts)	February 25, 2024		February 26, 2023		February 25, 2024		February 26, 2023
Numerator:
Net income (loss) from continuing operations	$	14,785	$	(11,330)	$	16,417	$	(27,238)

Income (loss) from discontinued operations, net of tax	847		(25,177)		2,679		(33,041)
Net income (loss)	$	15,632	$	(36,507)	$	19,096	$	(60,279)

Denominator:
Weighted average shares for basic income (loss) per share	30,488		30,304		30,450		29,838
Potential preferred stock conversion to common stock	5,899		—		5,792		—
Dilutive stock options and RSUs	222		—		227		—
Weighted average shares for diluted income (loss) per share	36,609		30,304		36,469		29,838

Basic net income (loss) per share:
Income (loss) from continuing operations	$	0.48	$	(0.37)	$	0.54	$	(0.91)
Income (loss) from discontinued operations	$	0.03	$	(0.83)	$	0.09	$	(1.11)
Total basic net income (loss) per share	$	0.51	$	(1.20)	$	0.63	$	(2.02)

Diluted net income (loss) per share:
Income (loss) from continuing operations	$	0.40	$	(0.37)	$	0.45	$	(0.91)
Income (loss) from discontinued operations	$	0.02	$	(0.83)	$	0.07	$	(1.11)
Total diluted net income (loss) per share	$	0.42	$	(1.20)	$	0.52	$	(2.02)

Restructuring Costs (Tables)

9 Months Ended

Feb. 25, 2024

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs


	Three Months Ended				Nine Months Ended
(in thousands)	February 25, 2024		February 26, 2023		February 25, 2024		February 26, 2023

Employee severance and benefit costs	$	76	$	2,187	$	215	$	2,282
Lease costs	684		43		700		88
Other restructuring costs	11		336		3		1,806
Total restructuring costs	$	771	$	2,566	$	918	$	4,176

The following table summarizes the restructuring costs recognized in the Company’s Condensed Consolidated Statements of Operations since the inception of the restructuring plan in fiscal year 2020 through February 25, 2024, excluding discontinued operations:


	Total
(in thousands)
Asset write-off costs, net	$	13,893
Employee severance and benefit costs	4,314
Lease costs	4,814
Other restructuring costs	7,853
Total restructuring costs	$	30,874


(in thousands)	May 28, 2023		Expense		Payments		February 25, 2024
Employee severance and benefit costs	$	1,600	$	215	$	(1,300)	$	515
Lease costs	257		700		(128)		829
Other restructuring costs	1,140		3		(923)		220
	$	2,997	$	918	$	(2,351)	$	1,564

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ (DEFICIT) EQUITY (Unaudited) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss
Convertible Preferred Stock, beginning balance (in shares) at May. 29, 2022	0
Convertible Preferred Stock, beginning balance at May. 29, 2022	$ 0
Convertible Preferred Stock, ending balance (in shares) at Aug. 28, 2022	0
Convertible Preferred Stock, ending balance at Aug. 28, 2022	$ 0
Beginning balance (in shares) at May. 29, 2022		29,513
Beginning balance at May. 29, 2022	87,823	$ 30	$ 167,352	$ (78,973)	$ (586)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock under stock plans, net of shares withheld (in shares)		80
Taxes paid by Company for employee stock plans	(67)		(67)
Stock-based compensation	785		785
Net income (loss)	(10,966)			(10,966)
Other comprehensive income, net of tax	300				300
Ending balance (in shares) at Aug. 28, 2022		29,593
Ending balance at Aug. 28, 2022	$ 77,875	$ 30	168,070	(89,939)	(286)
Convertible Preferred Stock, beginning balance (in shares) at May. 29, 2022	0
Convertible Preferred Stock, beginning balance at May. 29, 2022	$ 0
Convertible Preferred Stock, ending balance (in shares) at Feb. 26, 2023	39
Convertible Preferred Stock, ending balance at Feb. 26, 2023	$ 38,535
Beginning balance (in shares) at May. 29, 2022		29,513
Beginning balance at May. 29, 2022	87,823	$ 30	167,352	(78,973)	(586)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Convertible Preferred Stock PIK dividend	(428)
Net income (loss)	(60,279)
Ending balance (in shares) at Feb. 26, 2023		30,319
Ending balance at Feb. 26, 2023	$ 35,021	$ 30	174,243	(139,252)	0
Convertible Preferred Stock, beginning balance (in shares) at Aug. 28, 2022	0
Convertible Preferred Stock, beginning balance at Aug. 28, 2022	$ 0
Convertible Preferred Stock, ending balance (in shares) at Nov. 27, 2022	0
Convertible Preferred Stock, ending balance at Nov. 27, 2022	$ 0
Beginning balance (in shares) at Aug. 28, 2022		29,593
Beginning balance at Aug. 28, 2022	77,875	$ 30	168,070	(89,939)	(286)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock under stock plans, net of shares withheld (in shares)		76
Taxes paid by Company for employee stock plans	(142)		(142)
Stock-based compensation	1,108		1,108
Net income (loss)	(12,806)			(12,806)
Other comprehensive income, net of tax	286				286
Issuance of shares to Wynnefield Capital, Inc. (in shares)		628
Issuance of shares to Wynnefield Capital, Inc.	4,822		4,822
Ending balance (in shares) at Nov. 27, 2022		30,297
Ending balance at Nov. 27, 2022	$ 71,143	$ 30	173,858	(102,745)	0
Increase (Decrease) in Temporary Equity [Roll Forward]
Proceeds of convertible preferred stock, net of issuance costs (in shares)	39
Proceeds of Convertible Preferred Stock, net of issuance costs	$ 38,082
Convertible Preferred Stock paid-in-kind (“PIK”) dividend	428
Accretion of Convertible Preferred Stock	$ 25
Convertible Preferred Stock, ending balance (in shares) at Feb. 26, 2023	39
Convertible Preferred Stock, ending balance at Feb. 26, 2023	$ 38,535
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock under stock plans, net of shares withheld (in shares)		22
Convertible Preferred Stock PIK dividend	(428)		(428)
Accretion of Convertible Preferred Stock	(25)		(25)
Taxes paid by Company for employee stock plans	(65)		(65)
Stock-based compensation	903		903
Net income (loss)	(36,507)			(36,507)
Ending balance (in shares) at Feb. 26, 2023		30,319
Ending balance at Feb. 26, 2023	$ 35,021	$ 30	174,243	(139,252)	0
Convertible Preferred Stock, beginning balance (in shares) at May. 28, 2023	39
Convertible Preferred Stock, beginning balance at May. 28, 2023	$ 39,318
Increase (Decrease) in Temporary Equity [Roll Forward]
Convertible Preferred Stock paid-in-kind (“PIK”) dividend (in shares)	1
Convertible Preferred Stock paid-in-kind (“PIK”) dividend	$ 748
Accretion of Convertible Preferred Stock	$ 48
Convertible Preferred Stock, ending balance (in shares) at Aug. 27, 2023	40
Convertible Preferred Stock, ending balance at Aug. 27, 2023	$ 40,114
Beginning balance (in shares) at May. 28, 2023	30,322	30,322
Beginning balance at May. 28, 2023	$ (4,230)	$ 30	174,276	(178,536)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock under stock plans, net of shares withheld (in shares)		134
Issuance of stock under stock plans, net of shares withheld	724		724
Convertible Preferred Stock PIK dividend	(748)		(748)
Accretion of Convertible Preferred Stock	(48)		(48)
Taxes paid by Company for employee stock plans	(45)		(45)
Stock-based compensation	1,541		1,541
Net income (loss)	(10,754)			(10,754)
Ending balance (in shares) at Aug. 27, 2023		30,456
Ending balance at Aug. 27, 2023	$ (13,560)	$ 30	175,700	(189,290)	0
Convertible Preferred Stock, beginning balance (in shares) at May. 28, 2023	39
Convertible Preferred Stock, beginning balance at May. 28, 2023	$ 39,318
Convertible Preferred Stock, ending balance (in shares) at Feb. 25, 2024	42
Convertible Preferred Stock, ending balance at Feb. 25, 2024	$ 41,748
Beginning balance (in shares) at May. 28, 2023	30,322	30,322
Beginning balance at May. 28, 2023	$ (4,230)	$ 30	174,276	(178,536)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Convertible Preferred Stock PIK dividend	(2,287)
Net income (loss)	$ 19,096
Ending balance (in shares) at Feb. 25, 2024	30,547	30,547
Ending balance at Feb. 25, 2024	$ 17,686	$ 30	177,096	(159,440)	0
Convertible Preferred Stock, beginning balance (in shares) at Aug. 27, 2023	40
Convertible Preferred Stock, beginning balance at Aug. 27, 2023	$ 40,114
Increase (Decrease) in Temporary Equity [Roll Forward]
Convertible Preferred Stock paid-in-kind (“PIK”) dividend (in shares)	1
Convertible Preferred Stock paid-in-kind (“PIK”) dividend	$ 763
Accretion of Convertible Preferred Stock	$ 47
Convertible Preferred Stock, ending balance (in shares) at Nov. 26, 2023	41
Convertible Preferred Stock, ending balance at Nov. 26, 2023	$ 40,924
Beginning balance (in shares) at Aug. 27, 2023		30,456
Beginning balance at Aug. 27, 2023	(13,560)	$ 30	175,700	(189,290)	0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock under stock plans, net of shares withheld (in shares)		3
Convertible Preferred Stock PIK dividend	(763)		(763)
Accretion of Convertible Preferred Stock	(47)		(47)
Taxes paid by Company for employee stock plans	(12)		(12)
Stock-based compensation	1,585		1,585
Net income (loss)	14,218			14,218
Ending balance (in shares) at Nov. 26, 2023		30,459
Ending balance at Nov. 26, 2023	$ 1,421	$ 30	176,463	(175,072)	0
Increase (Decrease) in Temporary Equity [Roll Forward]
Convertible Preferred Stock paid-in-kind (“PIK”) dividend (in shares)	1
Convertible Preferred Stock paid-in-kind (“PIK”) dividend	$ 776
Accretion of Convertible Preferred Stock	$ 48
Convertible Preferred Stock, ending balance (in shares) at Feb. 25, 2024	42
Convertible Preferred Stock, ending balance at Feb. 25, 2024	$ 41,748
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock under stock plans, net of shares withheld (in shares)		88
Convertible Preferred Stock PIK dividend	(776)		(776)
Taxes paid by Company for employee stock plans	(42)		(42)
Stock-based compensation	1,499		1,499
Net income (loss)	15,632			15,632
Issuance of shares to Wynnefield Capital, Inc.	$ (48)		(48)
Ending balance (in shares) at Feb. 25, 2024	30,547	30,547
Ending balance at Feb. 25, 2024	$ 17,686	$ 30	$ 177,096	$ (159,440)	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Feb. 25, 2024	May 28, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	42,000	39,000
Preferred stock, shares outstanding (in shares)	42,000	39,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	30,547,000	30,322,000
Common stock, shares outstanding (in shares)	30,547,000	30,322,000

Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Feb. 25, 2024
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying Condensed Consolidated Balance Sheet as of May 28, 2023, which has been derived from audited financial statements, and the accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial information and with the instructions for Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, all adjustments (consisting of normal recurring accruals) have been made which are necessary to present fairly the financial position of the Company at February 25, 2024, and the results of operations and cash flows for all periods presented. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information normally included in financial statements and related footnotes prepared following GAAP have been condensed or omitted per the rules and regulations of the Securities and Exchange Commission (the “SEC”). The accompanying financial data should be reviewed in conjunction with the audited financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended May 28, 2023 (the “2023 Annual Report”). The Company restated its unaudited quarterly financial statements as of and for the three and nine months ended February 26, 2023 (the “Restatement”). Such restated and unaudited quarterly financial statements and related impacted amounts were presented in the Company’s Annual Report on Form 10-K for the year ended May 28, 2023. The discussion of financial results presented in this quarterly report on Form 10-Q reflects such restated amounts.
Fiscal Period	The Company’s fiscal year is the 52- or 53-week period that ends on the last Sunday of May with quarters within each year ending on the last Sunday of August, November, and February; however, in instances where the last Sunday would result in a quarter being 12-weeks in length, the Company’s policy is to extend that quarter to the following Sunday. A 14th week is included in the fiscal year every five or six years to realign the Company’s fiscal quarters with calendar quarters. The results reported in these interim condensed consolidated financial statements are not necessarily indicative of the results that may be reported for the entire year.
Basis of Consolidation	Basis of Consolidation The condensed consolidated financial statements are presented on the accrual basis of accounting in accordance with GAAP and include the accounts of the Company and its subsidiaries. All material inter-company transactions and balances have been eliminated.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make certain estimates and judgments that affect the amounts reported in the financial statements and accompanying notes. The accounting estimates that require management’s most significant and subjective judgments include revenue recognition; loss contingencies; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite-lived assets (including intangible assets and goodwill), and inventory; the valuation and recognition of stock-based compensation, and the valuation of the debt derivative liability. These estimates involve the consideration of complex factors and require management to make judgments. The analysis of historical and future trends can require extended periods of time to resolve and are subject to change from period to period. The actual results may differ from management’s estimates.
Concentrations of Risk	Concentrations of Risk Cash and cash equivalents and trade accounts receivable are financial instruments that potentially subject the Company to concentrations of credit risk. Our Company policy limits, among other things, the amount of credit exposure to any one issuer and to any one type of investment, other than securities issued or guaranteed by the U.S. government. The Company maintains cash in U.S. bank accounts, the balance of which may at times exceed the federally insured limit.
Inventories, net	Inventories, net Inventories primarily consist of in-process and finished goods related to sterile injectable pharmaceutical products in syringes, vials and cartridges. This includes premium, pharmaceutical grade HA in bulk form as well as formulated and filled syringes, vials and cartridges for injectable products used in treating a broad spectrum of medical conditions and procedures.
Fair Value Measurements	Fair Value Measurements The Company uses fair value measurement accounting for financial assets and liabilities and for financial instruments and certain other items measured at fair value. The Company has not elected the fair value option for any of its other eligible financial assets or liabilities. Applicable accounting guidance establishes a three-tier hierarchy for fair value measurements, which prioritizes the inputs used in measuring fair value as follows: Level 1 – observable inputs such as quoted prices for identical instruments in active markets. Level 2 – inputs other than quoted prices in active markets that are observable either directly or indirectly through corroboration with observable market data. Level 3 – unobservable inputs in which there is little or no market data, which would require the Company to develop its own assumptions. Cash is stated at cost, which approximates its fair value. The carrying amounts reported in the balance sheets for accounts receivable, accounts payable and accrued liabilities approximate fair value, due to their short-term maturities. Outstanding borrowings that qualify as financial instruments are carried at cost, which approximates their fair value as of February 25, 2024 and May 28, 2023, due to their short duration, except for the Alcon Research, LLC (“Alcon”) term debt with a fair value of $117.7 million that exceeds carrying value. The Term Loan Credit Facility (as defined in Note 6 Note 6 – Debt) contains embedded derivatives requiring bifurcation as a derivative instrument. The derivative liability related to the Term Loan Credit Facility is recorded as a discount to the long-term debt in the Condensed Consolidated Financial Statements. The embedded derivative liability is subject to remeasurement at the end of each reporting period, with changes in fair value recognized as a non-operating income (expense). The fair value of the embedded derivative liabilities associated with the Term Loan Credit Facility was estimated using a probability weighted discounted cash flow model to measure the fair value. This involves significant Level 3 inputs and assumptions including (i) an estimated probability and timing of a change in control and event of default, and (ii) a risk-adjusted discount rate.
Related Party Transactions	Related Party Transactions The Company has reflected the related party balances on the face of its financial statements beginning in the period which Alcon became a related party, which was as of May 22, 2023 at the time Alcon provided financing to the Company. Prior to providing financing, and continuing subsequently, Alcon was a customer of the Company.
Commitments and Contingencies	Commitments and Contingencies Legal Contingencies In the ordinary course of business, the Company is involved in various legal proceedings and claims. The Company makes a provision for a liability relating to legal matters when it is both probable that a liability has been incurred and the amount of the loss can be reasonably estimated. These provisions are reviewed at least each fiscal quarter and adjusted to reflect the impacts of negotiations, estimated settlements, legal rulings, advice of legal counsel and other information and events pertaining to a particular matter. Legal fees are expensed in the period in which they are incurred.
Accounting Pronouncements	Accounting Pronouncements In December 2023, the Financial Accounting Standards Board issued new guidance on income tax disclosures (ASU 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”). Among other requirements, this update adds specific disclosure requirements for income taxes, including: (1) disclosing specific categories in the rate reconciliation and (2) providing additional information for reconciling items that meet quantitative thresholds. The guidance is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years. Early adoption is permitted. The Company is in the process of evaluating the impact of the adoption of ASU 2023-09 on the Company’s condensed consolidated financial statements and disclosures. In November 2023, the FASB issued new guidance on segment reporting (ASU 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures”). The amendments in the ASU are intended to improve reportable segment disclosure requirements primarily through enhanced disclosures about significant segment expenses. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is in the process of evaluating the impact of the adoption of ASU 2023-07 on the Company’s condensed consolidated financial statements and disclosures.

Discontinued Operations

9 Months Ended

Feb. 25, 2024

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

As discussed in Note 1 – Organization, Basis of Presentation, and Summary of Significant Accounting Policies – Discontinued Operations, the Company completed the disposition of Yucatan and O Olive on February 7, 2023 and April 6, 2023, respectively. Yucatan and O Olive represented components of the Company’s previously operated food business and their sale represents a strategic shift in the Company going forward. Accordingly, concurrent with the execution of their respective purchase agreements, Yucatan and O Olive both met the accounting requirements for reporting as discontinued operations for all periods presented. There were no assets or liabilities of Yucatan and O Olive as of February 25, 2024.

The key components of income from discontinued operations for the three and nine months ended February 25, 2024 and February 26, 2023 were as follows (in thousands):


	Three Months Ended				Nine Months Ended
	February 25, 2024		February 26, 2023		February 25, 2024		February 26, 2023
Revenues	$	—	$	12,190	$	—	$	48,954
Cost of product sales	—		14,056		—		50,282
Gross profit	—		(1,866)		—		(1,328)
Operating costs and expenses:
Research and development	—		48		—		217
Selling, general and administrative	—		2,536		—		9,415
Impairment of intangible asset and goodwill	—		—		—		1,300
Loss on Sale of Yucatan	—		20,670		—		20,670

Restructuring costs	—		57		—		111
Total operating costs and expenses	—		23,311		—		31,713
Operating loss	—		(25,177)		—		(33,041)


Other income (expense), net	850		—		2,700		—
Income (loss) from discontinued operations before taxes	850		(25,177)		2,700		(33,041)
Income tax benefit (expense)	(3)		—		(21)		—
Income (loss) from discontinued operations, net of tax	$	847	$	(25,177)	$	2,679	$	(33,041)

Cash provided by operating activities by discontinued operations totaled $2.7 million and $0.1 million for the nine months ended February 25, 2024 and February 26, 2023, respectively. Cash used in investing activities by discontinued operations for the nine months ended February 26, 2023 was $0.1 million.

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Feb. 25, 2024	May 28, 2023
Current Assets:
Cash	$ 3,073	$ 19,091
Inventories, net	39,670	40,841
Prepaid expenses and other current assets	1,969	4,919
Total Current Assets	76,157	93,875
Property and equipment, net	145,367	134,390
Operating lease right-of-use assets	2,510	4,282
Goodwill	13,881	13,881
Intangible assets	4,200	4,200
Other long-term assets	4,126	2,917
Total Assets	246,241	253,545
Current Liabilities:
Accounts payable	15,685	22,097
Accrued compensation	4,070	4,145
Other accrued liabilities	8,892	7,142
Current portion of lease liabilities	4,159	1,270
Deferred revenues	3,200	4,100
Current portion of long-term debt, net, related party	773	580
Total Current Liabilities	36,810	39,289
Long-term debt, less current portion, net, related party	96,336	84,256
Revolving credit facility	19,913	16,809
Debt derivative liability, related party	23,000	64,900
Long-term lease liabilities, less current portion	5,088	9,709
Deferred taxes, net	607	380
Deferred revenues, less current portion, related party		2,900
Other non-current liabilities	5,053	174
Total Liabilities	186,807	218,457
Commitments and Contingencies, see Note 1
Convertible Preferred Stock, $0.001 par value; 2,000 shares authorized; 42 and 39 shares issued and outstanding at February 25, 2024 and May 28, 2023, respectively	41,748	39,318
Stockholders’ Deficit:
Common Stock, $0.001 par value; 50,000 shares authorized; 30,547 and 30,322 shares issued and outstanding at February 25, 2024 and May 28, 2023, respectively	30	30
Additional paid-in capital	177,096	174,276
Accumulated deficit	(159,440)	(178,536)
Total Stockholders’ Deficit	17,686	(4,230)
Total Liabilities, Convertible Preferred Stock, and Stockholders’ Deficit	246,241	253,545
Nonrelated Party
Current Assets:
Accounts receivable, less allowance for credit losses	19,427	19,907
Current Liabilities:
Deferred revenues	839	552
Related Party
Current Assets:
Accounts receivable, less allowance for credit losses	12,018	9,117
Current Liabilities:
Deferred revenues	2,392	3,503
Deferred revenues, less current portion, related party	$ 0	$ 2,940

Subsequent Events (Details)				3 Months Ended	12 Months Ended
Subsequent Events (Details)	Aug. 09, 2024 USD ($)	Jul. 08, 2024 USD ($) employee	May 10, 2024 USD ($)	Aug. 25, 2024 USD ($)	May 26, 2024 USD ($)	May 22, 2023 USD ($)
Revolving Credit Facility \| Revolving Credit Agreement
Subsequent Event [Line Items]
Revolving line of credit						$ 40,000,000
Subsequent Event
Subsequent Event [Line Items]
Cooperation agreement, expense					$ 400,000
Number of employees terminated \| employee		46
Percentage of position eliminated		9.00%
Severance related expenses		$ 1,000,000
Consideration received for lease adjustment	$ 2,400,000
Subsequent Event \| Forecast
Subsequent Event [Line Items]
Cooperation agreement, expense				$ 1,500,000
Subsequent Event \| Revolving Credit Facility \| Revolving Credit Agreement
Subsequent Event [Line Items]
Revolving line of credit			$ 40,000,000
Incremental borrowing capacity			$ 2,500,000
Basis spread on variable rate			4.25%
Incremental interest expense			$ 44,000
Payments of debt amendment fee			$ 50,000

Income Taxes	9 Months Ended
Income Taxes	Feb. 25, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The provision for income taxes from continuing operations for the three months ended February 25, 2024 and February 26, 2023, was an expense of $0.2 million and an expense of $70.0 thousand, respectively. The provision for income taxes from continuing operations for the nine months ended February 25, 2024 and February 26, 2023, was an expense of $0.2 million and an expense of $78.0 thousand, respectively. The effective tax rate for the three months ended February 25, 2024 and February 26, 2023 was 1.43% and 0.19%, respectively. The effective tax rate for the nine months ended February 25, 2024 and February 26, 2023 was 1.43% and 0.13%, respectively. The effective tax rate for the three and nine months ended February 25, 2024 and February 26, 2023, was lower than the statutory federal income tax rate of 21% primarily due to the movement of the valuation allowance recorded against certain deferred tax assets, partially offset by the federal and state research and development tax credits.

- Definition

The entire disclosure for income tax.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477891/740-270-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480990/946-20-50-13

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/740/tableOfContent

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-14

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-21

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-17

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482603/740-30-50-2

+ Details

Convertible Preferred Stock	9 Months Ended
Convertible Preferred Stock	Feb. 25, 2024
Equity [Abstract]
Convertible Preferred Stock	Convertible Preferred Stock On January 9, 2023, the Company issued an aggregate of 38,750 shares of the Series A Convertible Preferred Stock, par value $0.001 per share (the “Convertible Preferred Stock”), all of which are convertible into shares of common stock at the election of the holders of the Convertible Preferred Stock (each, a “Holder” and collectively, the “Holders”), subject to the exchange and beneficial ownership limitations described below. The Company recorded the Convertible Preferred Stock net of issuance costs of $0.7 million. Liquidation and Redemption As of February 25, 2024 and May 28, 2023, the aggregate liquidation preference of the Convertible Preferred Stock approximated $41.7 million and $39.3 million, respectively. Registration Rights Agreement On January 9, 2023, in connection with the issuance of the Convertible Preferred Stock, the Company and the Holders also entered into a Registration Rights Agreement (the “Registration Rights Agreement”) pursuant to which, among other things, the Company granted the Holders certain registration rights with respect to the shares of common stock issuable upon the conversion of the Convertible Preferred Stock. The Registration Rights Agreement contains monetary penalties if the Company fails to maintain the effectiveness of the registration statement. As of the February 25, 2024, the Company has accrued approximately $2.3 million in monetary penalties under the Registration Rights Agreement due to the delinquent filing of the Company’s annual and quarterly reports with the SEC. Classification The Convertible Preferred Stock is redeemable by the holders after June 29, 2026. Until such date, it is redeemable contingent upon the occurrence of certain events. As a result, the Company has presented the Convertible Preferred Stock outside of permanent equity. The Convertible Preferred Stock was recorded at its issuance date fair value of the net proceeds raised. The current carrying value approximates fair value as it reflects the accumulation of the PIK dividends and accretion of the issue costs. The Company recorded proceeds of $38.8 million, net of costs associated with the issuance of the Convertible Preferred Stock of approximately $0.7 million, approximating $38.1 million. The discount to the proceeds arising from issuance costs is being amortized up to its full redemption value through June 29, 2026. During the nine months ended February 25, 2024, the Company recorded PIK dividends of approximately $0.8 million as a reduction to Additional Paid-in Capital and an increased to the Convertible Preferred Stock balance. As of February 25, 2024 and May 28, 2023, there were approximately 41,679 shares and 39,420 shares, respectively, of Convertible Preferred Stock outstanding.

Stock-based Compensation and Stockholders' Equity (Tables)

9 Months Ended

Feb. 25, 2024

Share-Based Payment Arrangement [Abstract]

Share-Based Payment Arrangement, Activity

A summary of the activity under the Company’s stock option plans as of February 25, 2024 and changes during the fiscal year then ended is presented below:


	Options Outstanding	Weighted-Average Exercise Price Per Share		Total Intrinsic Value of Options Exercised (in thousands)		Weighted-Average Remaining Contractual Term (in Years)	Aggregate Intrinsic Value
Options outstanding at May 28, 2023	2,374,325	$	10.88
Options granted	6,300	$	7.51
Options exercised	(95,800)	$	9.38	$	115

Options expired	(119,850)	$	11.79
Options outstanding at February 25, 2024	2,164,975	$	10.88			1.21	$	—
Options exercisable at February 25, 2024	1,712,287	$	10.95			1.90	$	—

A summary of the Company’s restricted stock unit (“RSU”) award activity as of February 25, 2024 and changes during the fiscal year then ended is presented below:


	Restricted Stock Units Outstanding	Weighted-Average Grant Date Fair Value Per Share
Restricted stock units outstanding at May 28, 2023	336,791	$	9.70
Granted	1,058,556	$	8.25
Vested	(155,942)	$	8.03

Restricted stock units outstanding at February 25, 2024	1,239,405	$	8.67

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

The following table summarizes stock-based compensation by income statement line item:


	Three Months Ended				Nine Months Ended
(In thousands)	February 25, 2024		February 26, 2023		February 25, 2024		February 26, 2023
Continuing operations:
Cost of product sales	$	187	$	109	549		$	307
Research and development	42		31		126		173
Selling, general and administrative	1,265		763		3,928		2,316


Total stock-based compensation	$	1,494	$	903	$	4,603	$	2,796

Discontinued Operations - Components of Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024	Feb. 26, 2023
Operating costs and expenses:
Income (loss) from discontinued operations before taxes	$ 850	$ (25,177)	$ 2,700	$ (33,041)
Income tax (expense) benefit	(3)	0	(21)	0
Discontinued Operations \| Yucatan Foods And O Olive
Disposal Group, Including Discontinued Operation, Income Statement
Revenues	0	12,190	0	48,954
Cost of product sales	0	14,056	0	50,282
Gross profit	0	(1,866)	0	(1,328)
Operating costs and expenses:
Research and development	0	48	0	217
Selling, general and administrative	0	2,536	0	9,415
Impairment of intangible asset and goodwill	0	0	0	1,300
Restructuring costs	0	57	0	111
Total operating costs and expenses	0	23,311	0	31,713
Operating loss	0	(25,177)	0	(33,041)
Other income (expense), net	850	0	2,700	0
Income (loss) from discontinued operations before taxes	850	(25,177)	2,700	(33,041)
Income tax (expense) benefit	(3)	0	(21)	0
Income (loss) from discontinued operations, net of tax	847	(25,177)	2,679	(33,041)
Discontinued Operations \| Yucatan
Operating costs and expenses:
Loss on sale of business	$ 0	$ 20,670	$ 0	$ 20,670

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Feb. 25, 2024	Feb. 26, 2023
Cash flows from operating activities:
Net income (loss)	$ 19,096	$ (60,279)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Impairment of indefinite-lived intangible assets and goodwill	0	300
Depreciation and amortization	6,607	10,507
Accretion of debt discount, related party	0	0
Stock-based compensation expense	4,603	2,796
Deferred taxes	227	57
Interest expense PIK, related party	9,409	0
Change in debt derivative liability, related party	(41,900)	0
Provision for expected credit losses	77	200
Net gain on disposal of property and equipment held and used	19	0
Right-of-use asset impairment	1,402	0
Other, net	0	101
Changes in current assets and current liabilities:
Inventories	1,171	(14,847)
Prepaid expenses, other current assets, and other assets	1,586	(1,309)
Accounts payable	(4,617)	11,330
Accrued compensation	(75)	(1,895)
Other accrued liabilities	(200)	8,570
Net cash used in operating activities	(8,857)	(15,179)
Cash flows from investing activities:
Purchases of property and equipment	(15,284)	(14,309)
Net cash (used in) provided by investing activities	(15,284)	1,357
Cash flows from financing activities:
Proceeds from exercise of options	724	4,822
Proceeds from long-term debt	0	3,367
Payments on long-term debt	(386)	(3,199)
Proceeds from (payments on) revolving credit facility, net	3,104	(24,000)
Proceeds from working capital deposit	5,000	0
Principal payments on finance leases	(96)	0
Taxes paid by Company for employee stock plans	(99)	(274)
Payments for debt issuance costs	(124)	(3,669)
Proceeds from sale of preferred stock, net of issuance costs	0	38,082
Net cash provided by financing activities	8,123	15,129
Net (decrease) increase in cash	(16,018)	1,307
Cash, beginning of period	19,091	1,643
Cash, end of period	3,073	2,950
Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment in accounts payable	5,433	3,918
Capitalized interest expense	3,250	1,052
Convertible Preferred Stock PIK dividend	2,287	428
Nonrelated Party
Changes in current assets and current liabilities:
Accounts receivable	5,610	8,943
Deferred revenues	287	1,792
Related Party
Changes in current assets and current liabilities:
Accounts receivable	(8,108)	0
Deferred revenues	(4,051)	0
BreatheWay
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain on sale of divested business	0	(2,108)
Cash flows from investing activities:
Proceeds from the sale of net	0	15,666
Yucatan
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Gain on sale of divested business	$ 0	$ 20,663

Convertible Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended				9 Months Ended
	Jan. 09, 2023	Feb. 25, 2024	Nov. 26, 2023	Aug. 27, 2023	Feb. 26, 2023	Feb. 25, 2024	Feb. 26, 2023	May 28, 2023	Nov. 27, 2022	Aug. 28, 2022	May 29, 2022
Class of Stock [Line Items]
Proceeds of convertible preferred stock, net of issuance costs (in shares)					39,000
Registration rights agreement penalty		$ 2,300				$ 2,300
Proceeds from sale of preferred stock, net of issuance costs						0	$ 38,082
Proceeds of Convertible Preferred Stock, net of issuance costs					$ 38,082
Convertible Preferred Stock PIK dividend		$ 776	$ 763	$ 748	$ 428	$ 2,287	$ 428
Convertible preferred stock outstanding (in shares)		42,000	41,000	40,000	39,000	42,000	39,000	39,000	0	0	0
Series A Preferred Stock
Class of Stock [Line Items]
Proceeds of convertible preferred stock, net of issuance costs (in shares)	38,750
Temporary equity par value (usd per share)	$ 0.001
Stock issuance costs	$ 700					$ 700
Liquidation preference		$ 41,700				41,700		$ 39,300
Proceeds from sale of preferred stock, net of issuance costs						38,800
Proceeds of Convertible Preferred Stock, net of issuance costs						38,100
Convertible Preferred Stock PIK dividend						$ 800
Convertible preferred stock outstanding (in shares)		41,679				41,679		39,420

Organization, Basis of Presentation, and Summary of Significant Accounting Policies (Tables)

9 Months Ended

Feb. 25, 2024

Accounting Policies [Abstract]

Schedule of Disaggregation of Revenue

The following tables disaggregates revenue by major product lines and services (in thousands):


	Three Months Ended				Nine Months Ended
(In thousands)	February 25, 2024		February 26, 2023		February 25, 2024		February 26, 2023
Contact development and manufacturing organization	$	22,306	$	18,015	$	67,522	$	52,488
HA manufacturing	13,398		8,521		22,853		19,635

Total	$	35,704	$	26,536	$	90,375	$	72,123

Schedule of Inventories

As of February 25, 2024 and May 28, 2023, inventories consisted of the following (in thousands):


(In thousands)	February 25, 2024		May 28, 2023
Finished goods	$	13,113	$	13,141
Raw materials	18,686		17,735
Work in process	8,802		10,349
Inventory reserve	(931)		(384)
Total	$	39,670	$	40,841

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table summarizes the fair value of the Company’s assets and liabilities that are measured at fair value on a recurring and non-recurring basis (in thousands):


	Fair Value at February 25, 2024			Fair Value at May 28, 2023
	Level 1	Level 2	Level 3	Level 1	Level 2	Level 3








Liabilities:
Debt derivative liability(1)	—	—	23,000	—	—	64,900
Total liabilities	—	—	23,000	—	—	64,900

(1) As of February 25, 2024 and May 28, 2023, the fair value of the debt derivative liability is included in non-current liabilities in the Company’s Condensed Consolidated Balance Sheets.

Fair Value Measurement Inputs and Valuation Techniques

The risk adjusted discount rate as of February 25, 2024 and May 28, 2023, were as follows:


	February 25, 2024	May 28, 2023
Assumptions
Discount rate	21.3% — 24.2%	22.3% — 24.5%
Implied spread	17.0%	18.5%
Risk free rate	4.3% — 7.2%	3.8% — 6.0%

Schedule of Fair Value Reconciliation of Level 3

The following table reflects the fair value roll forward reconciliation of Level 3 assets and liabilities measured at fair value for the nine months ended February 25, 2024 (in thousands):


	Debt Derivative Liability
Balance as of May 29, 2022	$	—
Fair value on issuance(1)	$	64,900
Balance as of May 28, 2023	64,900
Decrease in fair value(2)	(41,900)
Balance as of February 25, 2024	$	23,000

(1)At May 28, 2023, the fair value of the embedded derivative liability approximated the fair value upon issuance on May 22, 2023.

- Definition

Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.

+ References + Details

Income Taxes (Details) - USD ($)	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($)	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024	Feb. 26, 2023
Income Tax Disclosure [Abstract]
Income tax expense (benefit)	$ 217,000	$ 70,000	$ 240,000	$ 78,000
Effective tax rate	(1.43%)	0.19%	(1.43%)	0.13%

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 231
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

+ Details

Earnings Per Share - Schedule of Basic and Diluted Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended						9 Months Ended
	Feb. 25, 2024	Nov. 26, 2023	Aug. 27, 2023	Feb. 26, 2023	Nov. 27, 2022	Aug. 28, 2022	Feb. 25, 2024	Feb. 26, 2023
Numerator:
Net income (loss) from continuing operations	$ 14,785			$ (11,330)			$ 16,417	$ (27,238)
Income (loss) from discontinued operations, net of tax	847			(25,177)			2,679	(33,041)
Net income (loss)	$ 15,632	$ 14,218	$ (10,754)	$ (36,507)	$ (12,806)	$ (10,966)	$ 19,096	$ (60,279)
Denominator:
Weighted average shares for basic net loss per share (in shares)	30,488			30,304			30,450	29,838
Potential preferred stock conversion to common stock (in shares)	5,899			0			5,792	0
Dilutive stock options and RSUs (in shares)	222			0			227	0
Weighted average shares for diluted net loss per share (in shares)	36,609			30,304			36,469	29,838
Basic net income (loss) per share:
Income (loss) from continuing operations (in dollars per share)	$ 0.48			$ (0.37)			$ 0.54	$ (0.91)
Loss from discontinued operations (in dollars per share)	0.03			(0.83)			0.09	(1.11)
Total basic net income (loss) per share (in dollars per share)	0.51			(1.20)			0.63	(2.02)
Diluted net income (loss) per share:
Income (loss) from continuing operations (in dollars per share)	0.40			(0.37)			0.45	(0.91)
Loss from discontinued operations (in dollars per share)	0.02			(0.83)			0.07	(1.11)
Total diluted net income (loss) per share (in dollars per share)	$ 0.42			$ (1.20)			$ 0.52	$ (2.02)

Stock-based Compensation and Stockholders' Equity - Summary of Stock-based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Feb. 25, 2024	Feb. 26, 2023	Feb. 25, 2024	Feb. 26, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 1,494	$ 903	$ 4,603	$ 2,796
Cost of product sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	187	109	549	307
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	42	31	126	173
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation	$ 1,265	$ 763	$ 3,928	$ 2,316

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Discontinued Operations - Narrative (Details) - Yucatan Foods And O Olive - Discontinued Operations: - USD ($) $ in Millions	9 Months Ended
	Feb. 25, 2024	Feb. 26, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash provided by operating activities	$ 2.7	$ 0.1
Cash used in investing activities		$ 0.1